Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

ICON Announces Agreement with Intel Allowing Integration of the Intel® Pharma Analytics Platform for Clinical Trials


ICON plc, (NASDAQ:ICLR) a global provider of drug development solutions
and services to the pharmaceutical, biotechnology and medical device
industries, today announced that it has agreed on preliminary deal terms
with Intel Corporation to enable ICON to offer the Intel®
Pharma Analytics Platform
for use in clinical trials. The Intel
platform is an edge-to-cloud artificial intelligence (AI) solution that
enables remote monitoring and continuous capture of clinical data from
study subjects using sensors and wearable devices, and can apply machine
learning techniques to objectively measure symptoms and quantify the
impact of therapies.

Jointly configured by ICON experts and building on Intel's AI and
analytics leadership, trials that leverage the Intel® Pharma Analytics
Platform can:

  • Capture de-identified, objective, high-quality, rich sensory data via
    sensors and wearable devices.
  • Get real-time information about protocol adherence while helping
    patients manage medication, perform structured tests and report
  • Utilize smartphone applications to collect electronic diaries and
    patient reported outcomes (PROs).
  • Transmit the de-identified data to a secured cloud infrastructure for
    storage and analysis.
  • Apply machine learning and other AI methods to objectively assess and
    quantify the severity of symptoms, quantify the impact of therapies
    such as medication efficacy or dose response.

The Intel® Pharma Analytics Platform provides benefits for
pharmaceutical companies seeking to speed and simplify clinical trials,
reduce trial costs, and gather more objective evidence; by transitioning
to automatic collection of consistent, unbiased data, remote monitoring
for data analysis, and delivering improved patient experience. These
changes will help accelerate time-to-market for new drugs, by producing
high-quality data and increasing patient retention, leading to shorter

Intel values individuals' privacy and employs technical and
organizational measures where appropriate to protect the privacy and
security of the personal data of the users of the Intel® Pharma
Analytics Platform, as required by Articles 28 and 32 GDPR and any other
applicable laws. Where appropriate, Intel performs data protection
impact assessments as required under Article 35 GDPR.

"Our engagement with Intel confirms ICON's position as the leading CRO
for advancing the use of wearable technology, and will expand ICON's
existing offering to include a service where data can be aggregated and
analysed from mhealth and wearable technologies, with advanced analytics
allowing for development of novel endpoints and digital biomarkers,"
commented Steve Cutler, CEO at ICON. "Furthermore, the platform
supports patient centric trial designs by reducing or eliminating the
need for patients to travel to sites, and can be integrated with our
Direct to Patient Call Centre (DPC) providing a seamless compliance
monitoring service."

"Intel is accelerating the pace of digital transformation, and IT plays
a leading role in delivering solutions on that journey," says Paula
Tolliver, Corporate Vice President and Chief Information Officer, Intel
Corporation. "With the power of AI, the Intel® Pharma Analytics Platform
helps the clinical trial industry reduce costs and deliver fresh
insights for drug development, potentially saving thousands of lives."

About ICON plc
ICON plc is a global provider of drug
development solutions and services to the pharmaceutical, biotechnology
and medical device industries. The company specialises in the strategic
development, management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical studies.
With headquarters in Dublin, Ireland, ICON currently, operates from 97
locations in 38 countries and has approximately 13,250 employees. More
information is at

This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at


View Comments and Join the Discussion!